

said antibodies, as well as the pharmaceutical compounds containing said antibodies. The invention also concerns a process for *in vitro* detection of nitrosylated proteins in a biologic specimen using said antibodies. --

In the Claims:

pe On pg. 89, line 2, kindly insert --We claim--.

E1 1. (Twice Amended) A purified antibody, wherein the antibody recognizes and binds specifically to a nitrosylated protein such that said purified antibody neutralizes the deleterious effects of excessive or inadequate production of nitric oxide or its conjugates in a subject.

11. (Three times amended) A pharmaceutical composition comprising:
(a) a purified antibody that recognizes and binds specifically to a nitrosylated protein; and
(b) a pharmaceutically acceptable excipient;
wherein said purified antibody neutralizes the deleterious effects of excessive or inadequate production of nitric oxide or its conjugates in a subject.

E2 14. (Three Times Amended) A kit for *in vitro* detection of nitrosylated proteins in biological specimen, comprising :
(a) a purified antibody that recognizes and binds specifically to a nitrosylated protein; and
(b) reagents to produce a medium favorable for an immunological reaction between said purified antibody and any nitrosylated proteins that may be present in a biological specimen.

E3 15. (New) A method of treating the deleterious effects of excessive or inadequate production of nitric oxide or its conjugates in a subject by administering to said subject a purified antibody wherein the antibody recognizes and binds specifically to a nitrosylated protein.

APPLICANTS:
U.S.S.N.:

Chagnaud *et al.*
09/331,980

16. (New) The method of claim 15, wherein the nitrosylated protein is a transporter of NO.

E3 17. (New) The method of claim 15, wherein the antibody binds specifically to nitrosylated albumin.

18. (New) The method of claim 15, wherein the antibody is a polyclonal antibody.

19. (New) The method of claim 15, wherein the antibody is a monoclonal antibody.

20. (New) The method of claim 15, wherein said excessive or inadequate production of nitric oxide may arise from infections, shock, degenerative diseases, diabetes, autoimmune diseases and cancers afflicting said subject.
